Skip to content
value.today

Whitehawk Therapeutics, Inc.

WHWK
$189 Mmarket cap on Oct 26, 2026
Compare
World rank
#16,455
Revenue
$7 M
For year ending December-2025
Net income
$-21 M
-288.5% margin
SEC filing
Employees
—

Whitehawk Therapeutics, Inc. in brief

Whitehawk Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Morristown, New Jersey, USA. Its market value was $189 M on 26 October 2026, which makes it the 16,455th largest listed company in the world and the 3,187th largest in the USA on this site. In the year to December 2025 it had sales of $7 M and a net loss of $21 M. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol WHWK (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Whitehawk Therapeutics, Inc.

We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.

In December 2024, we entered into an intellectual property license agreement with WuXi Biologics (Shanghai FX) Co., Ltd. for the development and global commercialization of a portfolio of three next generation antibody drug conjugates targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need. These ADCs are constructed utilizing an advanced linker-payload platform called CPT113 that has been shown to provide increased stability in blood circulation and deliver targeted release of a Topoisomerase I inhibitor payload into cancer cells.

From the company's annual report filed with the US SEC: read the report

Whitehawk Therapeutics, Inc. timeline

5 events, 2008–2025
  1. 2008
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed Aerpio Pharmaceuticals, Inc.
    Formerly Zeta Acquisition Corp Ii.
  5. 2021
  6. ✎
    Renamed Aadi Bioscience, Inc.
    Formerly Aerpio Pharmaceuticals, Inc..
  7. 2024
  8. 💰
    Record revenue of $26 million
    FY2024, the highest of the 7 years on record.
  9. 2025
  10. ✎
    Renamed Whitehawk Therapeutics, Inc.
    Formerly Aadi Bioscience, Inc..

Events of Whitehawk Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
26.5×
Price / book
1.4×
Free cash flow yield
-51.7%
Net margin
-288.5%
Operating margin
-1602.2%
Return on equity
-15.1%
Liabilities / assets
9.6%
Revenue growth
-72.5%
R&D / revenue
1273.9%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $20M, net income $-10M$20MFY18Fiscal year ending Dec 2019: revenue —, net income $-23M—FY19Fiscal year ending Dec 2020: revenue $14M, net income $-3M$14MFY20Fiscal year ending Dec 2021: revenue $14M, net income $-110M$14MFY21Fiscal year ending Dec 2022: revenue $15M, net income $-61M$15MFY22Fiscal year ending Dec 2023: revenue $24M, net income $-66M$24MFY23Fiscal year ending Dec 2024: revenue $26M, net income $-64M$26MFY24Fiscal year ending Dec 2025: revenue $7M, net income $-21M$7MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$7M-72.5%$-114M$-21M-288.5%
Dec 2024$26M+6.7%$-67M$-64M-245.2%
Dec 2023$24M+60.0%$-72M$-66M-270.1%
Dec 2022$15M+8.7%$-63M$-61M-397.6%
Dec 2021$14M0.0%$-111M$-110M-786.4%
Dec 2020$14M—$-3M$-3M-24.9%
Dec 2019——$-24M$-23M—
Dec 2018$20M—$-11M$-10M-51.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-97M$1M$-98M$-0.33—
Dec 2024$-60M$2M$-61M$-2.36—
Dec 2023$-60M$4M$-64M$-2.44—
Dec 2022$-50M$0M$-50M$-2.69—
Dec 2021$-22M$0M$-22M$-12.41—
Dec 2020$-13M$0M$-13M$-1.76—
Dec 2019$-24M$0M$-24M$-0.57—
Dec 2018$-6M$0M$-6M$-0.31—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $7M, net income $-18M$7MDec ’24Three months to Mar 2025: revenue $7M, net income $73M$7MMar ’25Three months to Jun 2025: revenue —, net income $-53M—Jun ’25Three months to Sep 2025: revenue —, net income $-18M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-23M—Dec ’25Three months to Mar 2026: revenue —, net income $-22M—Mar ’26Three months to Jun 2026: revenue —, net income $-17M—Jun ’26Three months to Sep 2026: revenue —, net income $-21M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-21M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Whitehawk Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$7 M
Operating income
$-114 M
Net income
$-21 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$151 M
Total liabilities
$15 M
Total equity
$136 M

As of December-2025

Top 91 institutional investors in Whitehawk Therapeutics, Inc.#

As of Sep 30, 2026
91 institutions held 44.0 M shares (about 74.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 56.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Whitehawk Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Yu Fan4,829,398-31,916 (-0.66%)8.18%$18 MNov 16, 2026
2Acuta Capital Partners, LLC4,685,9120 (0.00%)7.94%$18 MNov 16, 2026
3QVT Financial LP4,615,7090 (0.00%)7.82%$17 MNov 16, 2026
4Montanova Capital, LLC4,170,875-129,125 (-3.00%)7.07%$16 MNov 16, 2026
5Orbimed Advisors LLC3,853,472-80,824 (-2.05%)6.53%$14 MNov 16, 2026
6Avoro Capital Advisors LLC2,849,4020 (0.00%)4.83%$11 MNov 16, 2026
7BlackRock, Inc.2,589,723+666,895 (+34.68%)4.39%$10 MNov 13, 2026
8Siren, L.L.C.2,337,1020 (0.00%)3.96%$9 MNov 12, 2026
9KVP Capital Advisors, LP2,165,9970 (0.00%)3.67%$8 MNov 16, 2026
10Vanguard Capital Management LLC1,465,827+77,266 (+5.56%)2.48%$6 MNov 13, 2026
11ADAR1 Capital Management, LLC1,341,3940 (0.00%)2.27%$5 MNov 16, 2026
12Geode Capital Management, LLC1,055,562+155,782 (+17.31%)1.79%$4 MNov 6, 2026
13Acorn Capital Advisors, LLC932,139-207,224 (-18.19%)1.58%$4 MNov 16, 2026
14Renaissance Technologies LLC663,922+250,100 (+60.44%)1.13%$2 MNov 12, 2026
15State Street Corp591,672+204,690 (+52.89%)1.00%$2 MNov 12, 2026
16Two Sigma Investments, LP550,739+254,127 (+85.68%)0.93%$2 MNov 16, 2026
17Woodline Partners LP507,061+70,447 (+16.13%)0.86%$2 MNov 16, 2026
18Stempoint Capital LP495,980-525,057 (-51.42%)0.84%$2 MNov 16, 2026
19Millennium Management LLC442,900+62,494 (+16.43%)0.75%$2 MNov 16, 2026
20Acadian Asset Management LLC436,226+265,343 (+155.28%)0.74%$2 MNov 9, 2026
21Northern Trust Corp329,303+64,614 (+24.41%)0.56%$1 MNov 16, 2026
22Eversept Partners, LP303,171-135 (-0.04%)0.51%$1 MNov 16, 2026
23Vanguard Portfolio Management LLC296,030+76,813 (+35.04%)0.50%$1 MNov 13, 2026
24Vanguard Fiduciary Trust Co283,605+36,698 (+14.86%)0.48%$1 MNov 13, 2026
25Squarepoint Ops LLC206,513New0.35%$1 MNov 9, 2026
Show all 91: investors 26 to 91
Institutional investors 26 to 91 in Whitehawk Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Qube Research & Technologies Ltd197,064+148,071 (+302.23%)0.33%$1 MNov 13, 2026
27Goldman Sachs Group Inc196,509+69,751 (+55.03%)0.33%$1 MNov 16, 2026
28Verdad Advisers, LP153,698-147,785 (-49.02%)0.26%$1 MNov 16, 2026
29Bridgeway Capital Management, LLC115,284-50,000 (-30.25%)0.20%$0 MNov 16, 2026
30Charles Schwab Investment Management Inc105,867+27,035 (+34.29%)0.18%$0 MNov 16, 2026
31Dimensional Fund Advisors LP105,011+71,591 (+214.22%)0.18%$0 MNov 4, 2026
32Bank of New York Mellon Corp98,416+15,784 (+19.10%)0.17%$0 MNov 5, 2026
33UBS Group AG78,502+27,661 (+54.41%)0.13%$0 MNov 10, 2026
34Integrated Quantitative Investments LLC75,846New0.13%$0 MNov 13, 2026
35Jump Financial, LLC71,400+30,600 (+75.00%)0.12%$0 MNov 13, 2026
36American Century Companies Inc63,973+12,133 (+23.40%)0.11%$0 MNov 12, 2026
37Morgan Stanley63,133+33,153 (+110.58%)0.11%$0 MNov 13, 2026
38Nuveen, LLC54,530+10,731 (+24.50%)0.09%$0 MNov 10, 2026
39FMR LLC43,933+43,763 (+25742.94%)0.07%$0 MNov 10, 2026
40Invesco Ltd.43,888+4,709 (+12.02%)0.07%$0 MNov 12, 2026
41HRT Financial LP43,614New0.07%$0 MNov 13, 2026
42Deutsche Bank AG\36,657+4,989 (+15.75%)0.06%$0 MNov 6, 2026
43Bank Of America Corp /de/35,726+1,100 (+3.18%)0.06%$0 MNov 16, 2026
44XTX Topco Ltd35,666+17,144 (+92.56%)0.06%$0 MNov 16, 2026
45Susquehanna Portfolio Strategies, LLC29,148New0.05%$0 MNov 16, 2026
46Los Angeles Capital Management LLC28,380New0.05%$0 MNov 12, 2026
47Price T Rowe Associates Inc /MD/26,6090 (0.00%)0.05%$0 MNov 16, 2026
48MetLife Investment Management, LLC25,768New0.04%$0 MNov 16, 2026
49Rhumbline Advisers25,108+579 (+2.36%)0.04%$0 MNov 10, 2026
50Empirical Financial Services, LLC d.b.a. Empirical Wealth Management22,913New0.04%$0 MOct 27, 2026
51MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.20,839+5,897 (+39.47%)0.04%$0 MNov 16, 2026
52Jpmorgan Chase & Co20,752+7,179 (+52.89%)0.04%$0 MNov 12, 2026
53Vanguard Global Advisers, LLC19,702+225 (+1.16%)0.03%$0 MNov 13, 2026
54New York State Common Retirement Fund18,7000 (0.00%)0.03%$0 MNov 17, 2026
55Point72 Asset Management, L.P.18,012-39,117 (-68.47%)0.03%$0 MNov 16, 2026
56Susquehanna Fundamental Investments, LLC17,500New0.03%$0 MNov 16, 2026
57Barclays PLC17,321+10,888 (+169.25%)0.03%$0 MNov 6, 2026
58Graham Capital Management, L.P.15,703New0.03%$0 MNov 16, 2026
59Citadel Advisors LLC15,056-15,030 (-49.96%)0.03%$0 MNov 16, 2026
60AQR Capital Management LLC13,543New0.02%$0 MNov 16, 2026
61SEI Investments Co12,382New0.02%$0 MNov 10, 2026
62Spark Investment Management LLC11,400New0.02%$0 MNov 13, 2026
63Evergreen Capital Management LLC11,0000 (0.00%)0.02%$0 MOct 23, 2026
64BNP Paribas Financial Markets10,219+3,275 (+47.16%)0.02%$0 MNov 12, 2026
65Police & Firemen's Retirement System of New Jersey10,2050 (0.00%)0.02%$0 MNov 9, 2026
66Wells Fargo & Company/mn8,469-18,705 (-68.83%)0.01%$0 MNov 16, 2026
67Legal & General Group Plc4,152+990 (+31.31%)0.01%$0 MNov 16, 2026
68US Bancorp \de\3,3330 (0.00%)0.01%$0 MNov 5, 2026
69Russell Investments Group, Ltd.3,2700 (0.00%)0.01%$0 MNov 6, 2026
70Ameritas Investment Partners, Inc.2,9450 (0.00%)0.01%$0 MNov 13, 2026
71Tower Research Capital LLC (TRC)2,683+128 (+5.01%)0.00%$0 MNov 16, 2026
72Royal Bank Of Canada2,385+1,271 (+114.09%)0.00%$0 MNov 16, 2026
73Citigroup Inc2,130-12,889 (-85.82%)0.00%$0 MNov 4, 2026
74Osaic Holdings, Inc.1,5390 (0.00%)0.00%$0 MNov 12, 2026
75Bartlett & Co. Wealth Management LLC1,3330 (0.00%)0.00%$0 MNov 12, 2026
76Sterling Capital Management LLC848+194 (+29.66%)0.00%$0 MOct 22, 2026
77SBI Securities Co., Ltd.641+324 (+102.21%)0.00%$0 MOct 22, 2026
78Parkside Financial Bank & Trust550New0.00%$0 MOct 27, 2026
79Jones Financial Companies Lllp500New0.00%$0 MNov 13, 2026
80SJS Investment Consulting Inc.405New0.00%$0 MOct 26, 2026
81GAMMA Investing LLC286New0.00%$0 MOct 8, 2026
82Allworth Financial LP250New0.00%$0 MNov 17, 2026
83TD Waterhouse Canada Inc.2320 (0.00%)0.00%$0 MOct 16, 2026
84Farther Finance Advisors, LLC88New0.00%$0 MOct 8, 2026
85Caitong International Asset Management Co., Ltd47-98 (-67.59%)0.00%$0 MOct 29, 2026
86PNC Financial Services Group, Inc.39New0.00%$0 MNov 6, 2026
87Root Financial Partners, LLC30New0.00%$0 MOct 21, 2026
88Simplex Trading, LLC17-1 (-5.56%)0.00%$0 MNov 4, 2026
89EverSource Wealth Advisors, LLC10New0.00%$0 MNov 4, 2026
90Arax Advisory Partners8New0.00%$0 MNov 12, 2026
91Parallel Advisors, LLC80 (0.00%)0.00%$0 MNov 3, 2026

Mutual funds holding Whitehawk Therapeutics, Inc.#

49 funds hold shares worth $17 M (about 6.2% of the company). Since their previous reports 38 added shares and 4 sold, buying $8 M net.
Mutual funds holding Whitehawk Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.887,972$4 M1.5%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors734,137$3 M1.2%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.470,854$2 M0.80%<0.01%+20%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC352,173$1 M0.60%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors281,712$1 M0.48%<0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC192,391$1 M0.33%<0.01%−1.7%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors110,575$1 M0.19%0.03%+16%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.78,832$0 M0.13%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC62,161$0 M0.11%<0.01%+14%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC60,657$0 M0.10%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC57,711$0 M0.10%<0.01%−6.0%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC46,572$0 M0.08%<0.01%−7.3%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC45,075$0 M0.08%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC43,799$0 M0.07%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC34,206$0 M0.06%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation25,000$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust20,759$0 M0.04%<0.01%+2113%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.16,890$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.15,745$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.13,990$0 M0.02%<0.01%−30%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC15,506$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.13,000$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC9,220$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,165$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC7,372$0 M0.01%0.02%+5.4%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS7,328$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC7,202$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC5,917$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.5,074$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC4,933$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.4,892$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC4,413$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC3,800$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,990$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,990$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management2,945$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.3,459$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP3,330$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC2,594$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS2,884$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC2,642$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,742$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation1,704$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust1,254$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,249$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC974$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.819$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC702$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC200$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 49 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Whitehawk Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$2.6 M
14 sales, 3 insiders
Net, 12 months
-$2.6 M
open market only
Insiders on file
25
since
-$2.6 M$0Nov 2023: bought $0 (0 trades), sold $186 K (2 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $212 K (4 trades)Jan 2024: bought $0 (0 trades), sold $87 K (1 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $73 K (1 trades)Mar 2024: bought $0 (0 trades), sold $85 K (2 trades)MarApr 2024: bought $0 (0 trades), sold $91 K (2 trades)May 2024: bought $0 (0 trades), sold $77 K (1 trades)MayJun 2024: bought $0 (0 trades), sold $72 K (2 trades)Jul 2024: bought $0 (0 trades), sold $57 K (2 trades)JulAug 2024: bought $0 (0 trades), sold $57 K (3 trades)Sep 2024: bought $0 (0 trades), sold $68 K (1 trades)SepOct 2024: bought $0 (0 trades), sold $19 K (1 trades)Mar 2025: bought $0 (0 trades), sold $25 K (3 trades)MarMar 2026: bought $0 (0 trades), sold $32 K (3 trades)Apr 2026: bought $0 (0 trades), sold $2.6 M (11 trades)Apr
Bought (open market)Sold (open market)Hover a month for the totals
Whitehawk Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Anupam DalalDirectorGrant or awardindirect+1.28 M$3.920$5.0 M4.69 MForm 4
filed Caley CasteleinDirectorGrant or award+255,102$3.920$1000 K274,796Form 4
filed Bryan BallSee remarksGrant or award+51,020$3.920$200 K448,126Form 4
filed Margaret DuganChief Medical OfficerGrant or award+19,132$3.920$75 K19,132Form 4
filed David James LennonCHIEF EXECUTIVE OFFICER, DirectorGrant or award+51,021$3.920$200 K569,643Form 4
filed Scott M. GiacobelloCHIEF FINANCIAL OFFICERGrant or award+38,265$3.920$150 K333,489Form 4
filed Scott M. GiacobelloCHIEF FINANCIAL OFFICERSell-141,600$4.130$585 K295,224Form 4
filed Scott M. GiacobelloCHIEF FINANCIAL OFFICERSell-77,000$3.860$297 K436,824Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Whitehawk Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.5 M
5.3% of shares · 7.81 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-14.99 reverse split

Trading halts

  • 2025-03-19 13:32 UTC, code LUDP, resumed 13:37 UTC

Fails to deliver

  • : 188 shares at $3.21
  • : 61 shares at $3.70
  • : 1,345 shares at $4.20
  • : 68 shares at $4.39
  • : 2,775 shares at $4.76

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Whitehawk Therapeutics, Inc. scorecard#

Passes 3 of the 18 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.4×Price to book 1.4× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median26.5×Price to sales 26.5× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-51.7%Free cash flow is -51.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-72.5%Revenue down 72.5% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-22.3%-22.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-22.3%-22.3% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.33 vs -2.36Diluted EPS -0.33 in fiscal 2025 against -2.36 the year before (report's currency).
    • ✗Net income higher than five years earlier-$21 M-$21 M in fiscal 2025 against -$3 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$21 MNet income -$21 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-21.8%-21.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities10.3×Current ratio 10.26 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone3.16Z-score 3.16 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year129.0%Diluted shares up 129.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Whitehawk Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Whitehawk Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Net margin-288.5%-68.9%
Return on equity-21.8%-61.0%
Revenue growth, 3 years a year-22.3%12.9%
Revenue growth-72.5%15.8%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 72.5% against the year before.
  • Net loss of $21 million, the 16th loss-making year in a row.
  • Free cash flow was negative: -$98 million.
  • The share count rose 129.0% in the year.

Whitehawk Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Whitehawk Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue7.126241514r14r020——
Cost of revenue0.83.02.81.30—————
Research and development915149332015r13181211
Selling, general and administrative3037454019—————
General and administrative————192.1r9.8139.25.3r
Operating expenses————11217r24312117
Total costs and expenses122939678112—————
Operating income−114−67−72−63−111−2.5r−24−11−21−17r
Interest and finance income6.23.96.42.40.00.0————
Interest expense and finance costs00.20.20.20.70.8———0.0
Provision for credit losses————0.20.2————
Other non-operating income (expense)943.86.22.21.12.01.20.8−0.0−0.3
Income before tax−21−64−66−61−110−3.5————
Income tax00000.00.0————
Net income attributable to shareholders−21−64−66−61−110−3.5r−23−10−21−17r
Earnings per share, basic-0.33-2.36-2.44-2.69-12.41-1.76r-0.57-0.31-1.03-24.52r
Earnings per share, diluted-0.33-2.36-2.44-2.69-12.41-1.76r-0.57-0.31-1.03-24.52r
Shares, weighted average (basic)622727238.9—————
Shares, weighted average (diluted)622727238.92.5r4134220.9r
Balance sheet
Cash and cash equivalents382963391494.5r3963201.6r
Short-term investments10819461340————0.1
Receivables05.95.51.9014———0.0
Inventory05.36.41.90—————
Other current assets3.32.83.83.72.31.60.70.60.30.2
Current assets1496112518015119r4064212.2
Property, plant and equipment0.06.84.80.50.10.0r0.20.10.10.1
Right-of-use (leased) assets00.81.21.50.60.1r0.2———
Other intangible assets———03.80————
Total assets1517013218415819r4064212.4r
Accounts payable0.92.25.93.56.42.4r0.40.61.31.1r
Current liabilities151726191530r3.35.53.615r
Lease liabilities (non-current)00.60.81.30.5—0.1———
Total liabilities151827262231r3.45.5——
Retained earnings−353−333−269−203−143−33r−142−119−109−86r
Shareholders' equity13652105158136−12r−9.1r5917−86r
Total liabilities and equity1517013218415819r4064212.4r
Shares outstanding47252524212.5r4141271.2r
Cash-flow statement
Depreciation and amortization0.10.20.20.20.10.0————
Share-based compensation9.911129.62.10.1r1.13.40.60.5
Cash from operating activities−97−60−60−50−22−13r−24−5.8−19−0.0
Capital expenditure−0.6−1.7−4.0−0.4−0.0−0.0−0.2−0.0−0.0−0.1
Cash from investing activities122583−13325−0.0−0.2−0.00.0−0.1
Shares issued———01559.7—5240—
Dividends paid———0−4.4—————
Cash from financing activities940.10.3731421.2r—48370.0
Change in cash8.8−3424−110145−12r−244219−3.5r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Whitehawk Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product sales, net(total)$7 M100%

Business segments

  • Reportable$7 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Whitehawk Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.4 M
David Lennon
Other top executives, average
$2.0 M
the CEO earned 1.7× this
$100 invested is now
$19
Whitehawk Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025David Lennon$3.4 M$4.5 M$2.0 M$19
2024Chief executive$1.0 M$1.6 M$1.2 M$25
2023Chief executive$2.1 M$1.1 M$1.8 M$16

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Whitehawk Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 4 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 11

Whitehawk Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Acquisition or sale completed8-K
Bylaws or fiscal year changedResults announced8-K
Material agreementShareholder vote8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Restructuring8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Whitehawk Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$100 MPrivate placement after listing$50 to $250 million17equity, optionsSEC
Sep 2022$73 MPrivate placement after listing$50 to $250 million13equity, optionsSEC
Aug 2021$155 MPrivate placement after listing$50 to $250 million31equitySEC
Mar 2017$42 MPrivate placement after listing$10 to $50 million264equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Whitehawk Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
40
2019–2024
Latest
22 people
2024-08-16
Whitehawk Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024·······22····22
20217···········7
2019···11········11
Whitehawk Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
22 people (32% of workforce)Restructuring planSEC 8-K“(the “Company”) approved a plan of termination that will result in a workforce reduction of 22 employees, representing approximately 32% of the Company’s workforce.”Filing
7 people (58% of workforce)Restructuring planSEC 8-K“The plan reduces its current workforce by 7 employees, representing approximately 58% of the Company’s workforce.”Filing
11 people (41% of workforce)Restructuring planSEC 8-K“The realignment plan reduces its current workforce by 11 employees, representing approximately 41% of the Company’s workforce.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Whitehawk Therapeutics, Inc. compares in Biotechnology

  • Market cap$189 M · higher than 44% of 726
  • Revenue$7 M · higher than 39% of 647
  • Net margin-288.5% · higher than 20% of 408
  • Revenue growth-72.5% · higher than 9% of 438
  • Price / sales26.5× · lower than 26% of 339
  • Price / book1.4× · lower than 70% of 534
  • FCF yield-51.7% · higher than 23% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Whitehawk Therapeutics, Inc.🇺🇸$189 M—-288.5%-72.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Whitehawk Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Whitehawk Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Whitehawk Therapeutics, Inc.? Suggest a correction